CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

CIII nasal spray, marking the first monotherapy to be approved for adults with treatment-resistant depression (TRD).

On Tuesday, the FDA approved Johnson & Johnson’s (NYSE:JNJ) supplemental New Drug Application for Spravato (esketamine) CIII ...

Geriatric Depression Scale (GDS). Recent Evidence and Development ... Best Practices in Nursing Care to Older Adults," developed by the Hartford Institute for Geriatric Nursing.

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...

Stressed-out teenagers appear to be dragging down the U.S. economy, a new study says. Teenagers suffering from anxiety or ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...